Work

Avelumab first-line maintenance (1LM) in patients (pts) with advanced urothelial carcinoma (aUC) with or without diabetes mellitus (DM): Long-term outcomes from JAVELIN Bladder 100.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.869

Authors: Shilpa Gupta, Petros Grivas, Se Hoon Park, Daniel P. Petrylak, Karin Tyroller, Jason Hoffman, Joaquim Bellmunt

Institutions: Cleveland Clinic, University of Washington, Fred Hutch Cancer Center, Samsung Medical Center, Sungkyunkwan University, Yale University, EMD Serono, Inc. (United States), Merck Healthcare KGaA, Darmstadt (Germany), Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4407701460

Cites:

Cited by:

Related to: 10